Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Emergency aid for overdoses

  • Improving bladder function among people with spinal cord injuries

  • Blinded by non-science: Trivial scientific information increases trust in products

  • Pathological gambling is associated with altered opioid system in the brain

  • Highly connected CEOs more likely to broker mergers and acquisitions that harm firms, study shows

  • Heart rate may predict survival, brain function in comatose cardiac arrest survivors

  • Cold sores increase risk of dementia, research suggests

  • User-friendly electronic 'Eyecane' enhances navigational abilities for blind

  • Design of micro, nanoparticles to improve treatments for Alzheimer's, Parkinson's

  • Sexual preference for masculine men, feminine women is an urban habit

  •